Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
Cytokinetics, Incorporated furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025. The company provided these results via a press release dated November 5, 2025, which is included as Exhibit 99.1.
The information under Item 2.02 and Exhibit 99.1 is being furnished, not filed, and will not be incorporated into future Securities Act or Exchange Act filings unless expressly stated by the company.
Cytokinetics (CYTK) reported an insider transaction by its EVP, Research & Development. On 11/04/2025, the officer exercised 2,295 incentive stock options at $10.60 per share (code M) and sold 2,295 common shares at $59.55 (code S). Following these transactions, the officer held 140,610 common shares directly and retained 6,600 derivative securities (options).
Cytokinetics (CYTK) disclosed an insider transaction via Form 4. President & CEO and Director Mr. Blum reported a sale of 5,000 shares of common stock on 10/30/2025 at a price of $62.86 per share (transaction code S). Following the sale, he beneficially owns 358,108 shares directly.
He also reports indirect holdings of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported a Form 4 for a director. On 10/27/2025, the insider exercised 4,375 stock options at $10 and sold 4,375 common shares at $58.68 the same day. After these transactions, the director directly owned 32,444 shares.
The option exercised was a non-qualified stock option with a $10 exercise price, first exercisable on 02/04/2016 and expiring 01/04/2026; it is now fully exercised.
Cytokinetics (CYTK) disclosed a Form 4 for its EVP of Research & Development reporting insider transactions on 10/21/2025. The officer exercised 2,105 non-derivative shares via an option at $10.60 per share (code M) and sold 2,105 shares at $58.22 (code S) on the same date. Following these transactions, the reporting person directly holds 140,610 shares of common stock. A non-qualified stock option with an exercise price of $10.60, initially exercisable on 03/28/2017 and expiring on 02/28/2027, shows 1,000 derivative securities beneficially owned after the reported activity.
Cytokinetics, Inc. (CYTK) reported an insider transaction on Form 4. A company director acquired 99 shares of common stock on 10/15/2025 at a price of $62.8 per share. The filing notes the transaction code A (1), with the footnote stating, “Director equity in lieu of cash retainer program,” indicating this was a stock grant in place of cash fees.
Following the transaction, the director now beneficially owns 32,444 shares, held directly. No derivative securities were reported in this filing.
Cytokinetics (CYTK) reported an insider transaction. President & CEO sold 5,000 shares of common stock on 10/16/2025 at $60.03 per share. Following the sale, the reporting person beneficially owns 363,108 shares directly.
Additional indirect holdings are disclosed as 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
Cytokinetics (CYTK) director reported acquiring common stock. On 10/15/2025, the director acquired 99 shares at $62.8 per share under the director equity in lieu of cash retainer program. After this transaction, the director beneficially owns 30,873 shares, held directly.
Cytokinetics (CYTK) director Dr. Kaye reported an equity grant on 10/15/2025. The filing shows acquisition of 199 shares of common stock (Transaction Code A) at a reported price of $62.8, described as “director equity in lieu of cash retainer.” Following the transaction, Dr. Kaye beneficially owns 9,977 shares, held directly. This reflects routine director compensation paid in stock rather than cash.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 338 shares of common stock at $62.8 per share, noted as part of a director equity in lieu of cash retainer program.
Following the transaction, the director beneficially owned 74,578 shares direct and 83 shares indirect through a spouse.